Concord Biotech

Ahmedabad, India Founded: 2000 • Age: 26 yrs Listed
APIs and enzymes are manufactured through fermentation by the CDMO.
Request Access
Report Incorrect Data
Page last updated

About Concord Biotech

Concord Biotech is a publicly listed company based in Ahmedabad (India) founded in 2000 by Ankur Vaid. It operates as an APIs and enzymes are manufactured through fermentation by the CDMO. The company has 1,570 employees. Concord Biotech was last valued at $352.41 million in July 2016. Its Indian entity Concord Biotech Limited reported revenue of ₹888 Cr. Concord Biotech offers products and services including APIs, Formulations, and Contract Research and Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Its competitors include Almac Group, Indoco Remedies, BDR Pharmaceuticals Internationals, Aurobindo Pharma and Asymchem and 4 more; 4 of its 9 listed competitors have raised funding.

Company details

Founded in 2000 in Ahmedabad, India, the company operates as a CDMO in the pharmaceutical sector, specializing in research and production of fermentation-based semi-synthetic and synthetic APIs. Products cover immunosuppressants, antibiotics, oncology, antifungals, hypolipidemics, and enzymes. Services include strain improvement and contract fermentation manufacturing. Capabilities extend to solid orals, oral liquids, and suspensions compliant with global standards, with supplies provided internationally.

Recognitions & Rankings of Concord Biotech

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#259
Valuation
₹21,950 Cr
2023 #308
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹13,452 Cr

    CONCORDBIO · NSE

  • Share Price
    ₹1,270.00

    -1.23% today

  • Revenue
    ₹1,055 Cr

    FY 2025-26 · -12.1% YoY

  • EBITDA
    ₹365 Cr

    Margin 34.6%

  • Net Profit
    ₹239 Cr

    FY 2025-26 · -30.7% YoY

  • P/E (TTM)
    48.4x

    P/B 6.7x

  • ROE
    13.5%

    ROCE 18.0%

  • Investors
    Quadria Capital

    & 2 more

  • Employee Count
    1,570

Products & Services of Concord Biotech

Concord Biotech offers a comprehensive portfolio of products and services, including APIs, Formulations, and Contract Research and Manufacturing.

APIs
Active Pharmaceutical Ingredients

Manufactures fermentation and semi-synthetic APIs for therapeutic segments.

Formulations
Finished Pharmaceuticals

Produces nephrology and critical care formulations for global markets.

Contract Research and Manufacturing
Services

Offers formulation development and manufacturing services for APIs.

Apps and channels of Concord Biotech

its YouTube channel ConcordBiotech has 769 subscribers and 30 videos.

ConcordBiotech
YouTube 769 subscribers 30 videos Science & Technology
Open channel

Videos from Concord Biotech

The most watched videos on Concord Biotech's YouTube channel, ConcordBiotech (769 subscribers). Click a video to play it here.

API manufacturing facility - Limbasi
1.1K views
API manufacturing Facility - Dholka
535 views
Infection Prevention Week - Dr. Sudha Desai shares his expertise on infection prevention
482 views
Infection Prevention Week - Dr. Sanmay Chaudhary shares his expertise on infection prevention
382 views

More on ConcordBiotech.

Funding Insights of Concord Biotech

  • Total Rounds 2
  • Investors Count 3

All 2 funding rounds of Concord Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2016–Private Equity Round$352.41MQuadria Capital, Helix Investments
–
Jun 2009–Angel Round––
Rakesh Jhunjhunwala
Valuation history
DateValuationStage
Jul 2016$352.41M••••••••

Last known valuation $352.41M (Jul 2016). 3 investors in total: 2 institutional and 1 angel.

Investors in Concord Biotech

Concord Biotech has secured backing from 3 investors, including venture fund and angel investors. Prominent investors backing the company include Quadria Capital, Helix Investments and Rakesh Jhunjhunwala.

All
Venture Fund
Angel
InvestorDescriptionFounded YearDomainLocation
Quadria Capital
Healthcare private equity investments focused on Asian markets.
2012quadriacapital.comSingapore, Singapore
Helix Investments
Private equity firm focused on acquisitions
2007helix-investments.comPort Louis, Mauritius

Rakesh Jhunjhunwala

-
–unknown_98bab9ce6a794c459-
Premium access

Investor details for Concord Biotech

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Concord Biotech Limited (Concord Biotech)

Concord Biotech Limited is the primary company behind Concord Biotech. The board of Concord Biotech Limited currently have 10 directors; the longest-serving is Ravi Kapoor, appointed in 2003. 19 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ravi Kapoor
DIN 00003847
Director15 Dec 200322 yrs 10 moConcord Biotech Limited
Rajiv Ambrish Agarwal
DIN 00379990
Director30 Jun 200818 yrs 3 moConcord Biotech Limited
Sudhir Jairam Vaid
DIN 00055967
Managing Director14 Feb 201115 yrs 8 moConcord Biotech Limited
Ankur Vaid
DIN 01857225
Managing Director01 Sep 201115 yrs 1 moConcord Biotech Limited
Bharti Khanna
DIN 05147844
Director31 Jan 20179 yrs 8 moConcord Biotech Limited
Amitabh Gajendra Thakore
DIN 00016715
Director31 Jan 20179 yrs 8 moConcord Biotech Limited
Arvind Motilal Agarwal
DIN 00122921
Director24 May 20224 yrs 4 moConcord Biotech Limited
Jayaram Easwaran
DIN 02241192
Director14 Jun 20224 yrs 4 moConcord Biotech Limited
Chakravarthy Sriraman Mandayam
DIN 09631555
Director14 Jun 20224 yrs 4 moConcord Biotech Limited
Ekta Gupta
DIN 01095961
Director01 Jun 20264 moConcord Biotech Limited

People of Concord Biotech

52 people are tracked at Concord Biotech (16 in leadership, 36 in team); the tracked headcount is 1,570.

NameRoleGroup
Ankur Vaid
FounderLeadership
Amit Varma
DirectorLeadership
Ravi Kapoor
DirectorLeadership
Rajiv Ambrish Agarwal
DirectorLeadership
Satish Khanna
DirectorLeadership
Dharnidhar Mistri
General Manager EngineeringLeadership
Dipak Mehta
Assistant General Manager HR & AdminLeadership
Dr. Manoj Kumar
Technical Vice President & Site HeadLeadership
Sunil Kumar Bajaj
President-pharmaceutical BusinessLeadership
Rajkumar Awachar
General Manager QualityLeadership
Amit Gupta
Deputy General Manager MarketingLeadership
Lalit Sethi
Chief Financial OfficerLeadership
Niraj Bhatt
General Manager EngineeringLeadership
Nitin Mishra
Senior General ManagerLeadership
Anoop Dixit
Senior Vice President Sales MarketingLeadership
Sonal Kumra
Director Business DevelopmentLeadership
Arun Patel
Manager Packaging DevelopmentTeam
Sandeep Kumar
Regional Business ManagerTeam
Kiritsinh Jadeja
Utility EngineeringTeam
Sandeep Srivastva
Regional Business ManagerTeam

32 more people are available in the full profile.

Premium access

Complete people profiles for Concord Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Concord Biotech

Concord Biotech is a publicly listed company on the NSE with ticker symbol CONCORDBIO in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date18 Aug 2023
  • Listed onBSE: 543960 · NSE: CONCORDBIO
  • Listed entityConcord Biotech Ltd.
  • Exchange sectorCommercial services
  • ISININE338H01029
  • Share price₹1,382.10 (+0.91% on the day) · 2026-10-14
  • Market capitalisation₹14,314 Cr
  • Price to earnings52.5
  • EPS (diluted, trailing year)₹26.32
  • Dividend yield0.55%
  • Volume (last session)63,724

Financials of Concord Biotech

Exchange-reported figures of Concord Biotech Limited, the listed company behind Concord Biotech (NSE: CONCORDBIO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,055 Cr
-12.1% YoY
EBITDA
₹365 Cr
-27.9% YoY
Profit After Tax
₹239 Cr
-30.7% YoY
Net Worth
₹2,017 Cr
+11.3% YoY
Total Assets
₹2,021 Cr
+11.1% YoY
Total Debt
₹2.32 Cr
-21.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,0551,2001,017853713616512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.7%+20.3%-
EBITDA365506432344270327205
EBITDA margin+34.6%+42.1%+42.5%+40.3%+37.9%+53.1%+39.9%
Profit before tax345495413322238313214
Net profit239344298237171230152
Net profit margin+22.6%+28.7%+29.3%+27.8%+24.0%+37.4%+29.6%
EPS (₹)24.9435.5229.4522.95183.93247.44177.82
Balance sheet
Total assets2,0211,8191,5381,3241,1681,089824
Net worth2,0171,8131,5271,2901,103999770
Total debt2.322.979.7431.5562.5086.3552.06
Cash & bank13.581.1847.0243.4588.9360.822.59
Net working capital680637518424435391239
Cash flow
Cash from operations267245265246207167155
Cash from investing(143)(160)(155)(158)(112)(195)(114)
Cash from financing(113)(98.77)(99.21)(85.22)(100)31.37(42.52)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue257326278247204430244310
Revenue growth (YoY)+26.2%-24.2%+13.7%-20.4%-5.5%---
Other income14.1015.359.9815.6415.179.3816.5610.03
EBITDA82.3811895.0188.4961.4018997.95134
EBITDA margin+32.0%+36.3%+34.2%+35.8%+30.1%+43.9%+40.1%+43.1%
Depreciation18.1019.5418.7518.3917.7814.6213.2613.31
Interest0.040.080.080.060.060.100.100.10
Profit before tax78.3411486.1685.6858.73184101130
Tax20.6525.6122.5222.6314.6843.1625.2334.59
Net profit57.6988.4763.6463.0544.0514075.9295.75
EPS (₹)5.528.466.086.034.2113.427.269.15
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,0551,2001,017853713617512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.6%+20.4%-
EBITDA374507432344274328205
EBITDA margin+35.4%+42.2%+42.5%+40.3%+38.4%+53.2%+39.9%
Profit before tax351496409320241313213
Net profit241345294235175230151
Net profit margin+22.8%+28.8%+28.9%+27.6%+24.5%+37.3%+29.6%
EPS (₹)25.1735.6529.1322.76187.76247.44177.66
Balance sheet
Total assets2,0241,8181,5371,3261,1721,091824
Net worth2,0201,8131,5251,2921,1071,000770
Total debt0.632.979.7431.5562.5089.2852.06
Cash & bank9.281.1847.0243.4588.9360.822.59
Net working capital676637518425438392239
Cash flow
Cash from operations264245265246207167155
Cash from investing(142)(160)(155)(158)(112)(195)(114)
Cash from financing(115)(98.77)(99.21)(85.22)(100)31.12(42.52)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue261326278247204430244310
Revenue growth (YoY)+27.7%-24.2%+13.9%-20.4%-5.5%---
Other income13.1015.5410.0813.4313.689.3814.7310.03
Total expenses173204179157143239146174
EBITDA87.1812298.9490.5461.4019097.95137
EBITDA margin+33.5%+37.6%+35.6%+36.6%+30.1%+44.3%+40.1%+44.1%
Depreciation18.0519.4918.6718.3917.7814.6213.2613.31
Interest0.020.060.060.060.060.100.100.10
Profit before tax82.2111890.2985.5257.2418599.32133
Tax21.0228.3622.5222.6314.6843.1625.2334.59

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 21 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue257326278247204430244310
Revenue growth (YoY)+26.2%-24.2%+13.7%-20.4%-5.5%---
Other income14.1015.359.9815.6415.179.3816.5610.03
EBITDA82.3811895.0188.4961.4018997.95134
EBITDA margin+32.0%+36.3%+34.2%+35.8%+30.1%+43.9%+40.1%+43.1%
Depreciation18.1019.5418.7518.3917.7814.6213.2613.31
Interest0.040.080.080.060.060.100.100.10
Profit before tax78.3411486.1685.6858.73184101130
Tax20.6525.6122.5222.6314.6843.1625.2334.59
Net profit57.6988.4763.6463.0544.0514075.9295.75
EPS (₹)5.528.466.086.034.2113.427.269.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,0551,2001,017853713616512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.7%+20.3%-
Other income55.2644.4537.1537.2723.4214.1031.52
Total expenses690695585509443289308
Employee cost17713912311095.6964.2562.24
EBITDA365506432344270327205
EBITDA margin+34.6%+42.1%+42.5%+40.3%+37.9%+53.1%+39.9%
Depreciation74.4654.3753.5954.0350.0527.5221.25
Interest0.821.043.185.186.130.901.17
Profit before tax345495413322238313214
Tax85.4212310481.9362.5977.8344.53
Net profit239344298237171230152
Net profit margin+22.6%+28.7%+29.3%+27.8%+24.0%+37.4%+29.6%
EPS (₹)24.9435.5229.4522.95183.93247.44177.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.4610.4610.4610.469.519.519.51
Reserves & surplus2,0071,8021,5161,2801,094990761
Shareholders' funds (net worth)2,0171,8131,5271,2901,103999770
Minority interest(1.92)0.000.000.000.000.000.00
Secured loans0.000.386.2331.2460.5961.3535.53
Unsecured loans2.322.593.510.311.9125.0016.53
Total debt2.322.979.7431.5562.5086.3552.06
Total liabilities2,0211,8191,5381,3241,1681,089824
Assets
Gross block1,1611,095826792720643310
Net block789795575593573546240
Capital work in progress79.3250.6621117374.1617.95141
Investments49133524613773.73141199
Inventories326240208212195154111
Sundry debtors460522350274232178184
Cash & bank balances13.581.1847.0243.4588.9360.822.59
Loans & advances47.9256.2047.9461.2542.9774.2243.37
Total current assets848819653591559466341
Total current liabilities16818213416712475.64102
Net working capital680637518424435391239
Total assets2,0211,8191,5381,3241,1681,089824
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.9015.143.500.675.142.413.76
Net cash from operating activities267245265246207167155
Net cash from investing activities(143)(160)(155)(158)(112)(195)(114)
Net cash from financing activities(113)(98.77)(99.21)(85.22)(100)31.37(42.52)
Net change in cash11.28(14.24)11.642.83(4.48)2.74(1.35)
Closing cash13.581.1847.0243.4588.9360.822.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-12.1%+18.0%+19.2%+19.7%+15.7%+20.3%-
EBITDA growth-27.9%+17.0%+25.6%+27.3%-17.5%+60.1%-
PBT growth-30.3%+19.9%+28.1%+35.6%-24.2%+46.6%+9997.0%
Net income growth-30.7%+15.6%+25.4%+38.8%-25.7%+51.9%-
Revenue CAGR (3Y)+7.3%+19.0%+18.2%+18.5%---
EBITDA CAGR (3Y)+2.0%+23.2%+9.7%+18.9%---
Profitability & leverage
Net income margin+24.6%+31.0%+30.3%+28.1%+24.5%+38.2%+33.0%
Return on capital employed+18.0%+29.5%+29.1%+26.3%+21.6%+32.8%+23.2%
Return on net worth+13.5%+22.3%+21.9%+20.1%+16.6%+26.6%+19.7%
Debt / equity0.000.000.010.040.070.080.07
Long-term debt / equity0.000.000.000.020.040.050.05
Interest cover0.280.230.841.792.780.300.64
Efficiency & per share
Fixed asset turnover0.931.251.261.131.051.291.65
Inventory turnover3.735.364.844.194.094.654.61
Debtors turnover2.152.753.263.373.483.412.79
EPS (₹)24.9435.5229.4522.95183.93247.44177.82
Dividend per share (₹)7.5510.708.756.835.120.0039.25
Book value per share (₹)192.81173.27145.93123.311,159.991,050.80809.87
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue261326278247204430244310
Revenue growth (YoY)+27.7%-24.2%+13.9%-20.4%-5.5%---
Other income13.1015.5410.0813.4313.689.3814.7310.03
Total expenses173204179157143239146174
EBITDA87.1812298.9490.5461.4019097.95137
EBITDA margin+33.5%+37.6%+35.6%+36.6%+30.1%+44.3%+40.1%+44.1%
Depreciation18.0519.4918.6718.3917.7814.6213.2613.31
Interest0.020.060.060.060.060.100.100.10
Profit before tax82.2111890.2985.5257.2418599.32133
Tax21.0228.3622.5222.6314.6843.1625.2334.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,0551,2001,017853713617512
Revenue growth-12.1%+18.0%+19.2%+19.7%+15.6%+20.4%-
Other income52.7344.4533.7835.3123.4213.8131.37
Total expenses681693585509439289308
Employee cost17013912311095.6969.4762.24
EBITDA374507432344274328205
EBITDA margin+35.4%+42.2%+42.5%+40.3%+38.4%+53.2%+39.9%
Depreciation74.3354.3753.5954.0350.0527.5221.25
Interest0.771.043.185.186.131.051.17
Profit before tax351496409320241313213
Tax88.1612310481.9362.5977.8344.53
Net profit241345294235175230151
Net profit margin+22.8%+28.8%+28.9%+27.6%+24.5%+37.3%+29.6%
EPS (₹)25.1735.6529.1322.76187.76247.44177.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.4610.4610.4610.469.519.519.51
Reserves & surplus2,0091,8021,5151,2821,098990761
Shareholders' funds (net worth)2,0201,8131,5251,2921,1071,000770
Secured loans0.000.386.2331.2460.5986.3535.53
Unsecured loans0.632.593.510.311.912.9316.53
Total debt0.632.979.7431.5562.5089.2852.06
Total liabilities2,0241,8181,5371,3261,1721,091824
Assets
Gross block1,1591,095826792720644310
Net block786795575593573546240
Capital work in progress79.3250.6621117374.1617.95141
Investments48833524413874.39142199
Inventories326240208212195154111
Sundry debtors461522350274232178184
Cash & bank balances9.281.1847.0243.4588.9360.822.59
Loans & advances47.5856.2047.9461.2542.9774.2243.37
Total current assets843819653591559466341
Total current liabilities16718213416512174.34102
Net working capital676637518425438392239
Total assets2,0241,8181,5371,3261,1721,091824
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.9015.143.500.675.142.413.76
Net cash from operating activities264245265246207167155
Net cash from investing activities(142)(160)(155)(158)(112)(195)(114)
Net cash from financing activities(115)(98.77)(99.21)(85.22)(100)31.12(42.52)
Net change in cash6.98(14.24)11.642.83(4.48)2.74(1.35)
Closing cash9.281.1847.0243.4588.9360.822.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-12.1%+18.0%+19.2%+19.7%+15.6%+20.4%-
EBITDA growth-26.3%+17.3%+25.6%+25.6%-16.5%+60.3%-
PBT growth-29.1%+21.2%+27.8%+32.7%-23.0%+46.7%+20.0%
Net income growth-30.3%+17.4%+25.0%+34.8%-24.1%+51.9%-
Revenue CAGR (3Y)+7.3%+19.0%+18.1%+18.5%+17.8%+22.0%+22.9%
EBITDA CAGR (3Y)+2.8%+22.8%+9.6%+18.9%+14.9%+31.3%+14.8%
Profitability & leverage
Net income margin+25.0%+31.1%+30.0%+27.9%+25.1%+38.2%+33.0%
Return on capital employed+18.3%+29.6%+28.8%+26.1%+21.9%+32.8%+25.2%
Return on net worth+13.7%+22.4%+21.6%+19.9%+17.0%+26.6%+20.9%
Debt / equity0.000.000.010.040.070.080.04
Long-term debt / equity0.000.000.000.020.040.050.03
Interest cover0.260.230.841.792.740.350.64
Efficiency & per share
Fixed asset turnover0.941.251.261.131.051.291.73
Inventory turnover3.735.364.844.194.094.665.05
Debtors turnover2.152.753.263.373.483.423.00
EPS (₹)25.1735.6529.1322.76187.76247.44177.66
Dividend per share (₹)7.5510.708.756.835.120.0039.25
Book value per share (₹)193.06173.27145.80123.501,164.131,051.11809.71

Timeline of Concord Biotech

5 dated milestones of Concord Biotech across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded Concord Biotech is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Private Equity Round,.
  4. Milestone Reaches Minicorn status.
  5. IPO Lists on the stock exchange (IPO).

Competitors of Concord Biotech

Concord Biotech has 9 listed competitors in our database, 4 of them funded. They include Almac Group, Indoco Remedies, BDR Pharmaceuticals Internationals, Aurobindo Pharma and Asymchem, among others.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Almac Group
almacgroup.com2001Craigavon, United Kingdom$338.8M2,109
Integrated CDMO services for biopharma R&D and manufacturing are offered.
Indoco Remedies
indoco.com1947Mumbai, India–6,291
APIs manufacturing and formulation services are provided in therapeutic segments.
BDR Pharmaceuticals Internationals
bdrpharma.com2003Mumbai, India$88.16M1,864
APIs and finished products are developed and manufactured.
Aurobindo Pharma
aurobindo.com1986Hyderabad, India–1,010
Generic biocatalytic solutions are provided for pharmaceutical applications.
Asymchem
asymchem.com1995Morrisville, United States–48
APIs and peptides are developed and manufactured by Asymchem.
Seqens
seqens.com2003Ecully, France–44
Contract manufacturing services for small molecules and peptides are provided.
Continuus Pharma
continuuspharma.com2012Woburn, United States$7.73M47
MIT-Novartis spinoff offering continuous manufacturing solutions to remove the proverbial wall between API and FDF manufacturing in small molecule development
Biophore
biophore.com2007Hyderabad, India$2.74M639
Niche generic pharmaceuticals are developed and manufactured for industry needs.
Pharmaceutics International
pharm-int.com1994Hunt Valley, United States–248
Pharmaceutical dosage forms are manufactured by this CDMO.
Premium access

Detailed competitors of Concord Biotech

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Concord Biotech

The website of Concord Biotech (concordbiotech.com) receives about 3.7K visits a month and ranks #4,215,278 among all websites worldwide, #5,205 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.7K

    ▼ 2.4% vs previous month

  • Unique visitors
    1.8K

    per month

  • Global rank
    #4,215,278

    among all websites

  • Category rank
    #5,205

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Concord Biotech. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Swiss Pharma
swisspharma.in
100%
1.3K#10,147,211View details
Nilrise Pharma
nilrisepharma.com
94%
–#3,419,796View details
Insud Pharma
insudpharma.com
93%
14.6K#1,472,055View details
Alembic Pharmaceuticals
alembicpharmaceuticals.com
89%
23K#2,083,600View details
Coral Drugs
coraldrugs.com
88%
680.7K#11,178,852View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 25 similar websites and full traffic analytics for Concord Biotech

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 25 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Biopharma Outsourcing & Drug Delivery

10 companies that operate in the same segment as Concord Biotech (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M1,820
Evotec
Drug discovery and development services are provided to biopharma sector.
1993Hamburg, Hamburg, GermanyUSD 25 MUSD 926.33 M4,830
Pharmaron
Drug discovery and development services for small molecules are provided.
2003Beijing, ChinaUSD 320 M–476
Indegene
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M4,490
Insulet
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
MannKind Corp
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Pfizer
Pharmaceutical products for treating multiple diseases are provided.
1849New York, New York, United StatesUSD 8 MUSD 266.99 M1,770
LabCorp
Provider of laboratory tests for physicians
1969Burlington, Vermont, United States–USD 13.95 B70,000
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Concord Biotech

Stock Alert: Avantel, IOL Chem, Concord Biotech,ESAF SFB, NSE | Capital Market News - Business Standard
Business Standard • 27 days ago
Buzzing Stocks: Max Estates gains 6% on JDA; Concord Biotech rises 4% after bonus share approval
Moneycontrol • 27 days ago
1:1 Bonus Issue: Concord Biotech announces free shares; check update on record date
ZEE Business • 28 days ago
Stocks to Watch for September 24: NTPC, Bharat Dynamics, Exide Industries, Concord Biotech and more - CNBC TV18
CNBCTV18 • 28 days ago
Concord Biotech announces 1:1 bonus share issue; shareholders to get one free share for each held - CNBC TV18
CNBCTV18 • 28 days ago
Concord Biotech: Approves 1:1 Bonus Share Plan And Raises Authorized Capital To ₹22 Crore
Exchange Update • 28 days ago
Concord Biotech's Valthera unit completes US FDA audit with one procedural observation | Capital Market News - Business Standard
Business Standard • 1 month ago
Bertelsmann And Great Mountain Partners Complete Combination Of BMG And Concord
Reuters • 1 month ago
Ashish Dhawan buys additional over 1% stake in Religare Enterprises for second consecutive session
Moneycontrol • 1 month ago
Volumes spurt at Concord Biotech Ltd counter | Capital Market News - Business Standard
Business Standard • 1 month ago
Premium access

Complete news archive for Concord Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Concord Biotech

Concord Biotech was founded in 2000 and raised its 1st funding round 9 years after it was founded.

Concord Biotech is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Concord Biotech has 1,570 employees.

The primary company behind Concord Biotech, Concord Biotech Limited, reported revenue of ₹888 Cr for FY 2023, up 21% year on year.

Founded in 2000 in Ahmedabad, India, the company operates as a CDMO in the pharmaceutical sector, specializing in research and production of fermentation-based semi-synthetic and synthetic APIs. Products cover immunosuppressants, antibiotics, oncology, antifungals, hypolipidemics, and enzymes. Services include strain improvement and contract fermentation manufacturing. Capabilities extend to solid orals, oral liquids, and suspensions compliant with global standards, with supplies provided internationally.

Concord Biotech's top competitors include BDR Pharmaceuticals Internationals, Almac Group and Indoco Remedies.

Concord Biotech offers APIs, Formulations, and Contract Research and Manufacturing.

Yes, Concord Biotech is publicly traded on NSE under the ticker symbol CONCORDBIO.

Concord Biotech has 3 investors. Key investors include Quadria Capital, Helix Investments, and Rakesh Jhunjhunwala.

The valuation of Concord Biotech is $352.41M as of Jul 2016.

Concord Biotech operates through Concord Biotech Limited.

The legal entities of Concord Biotech currently have 12 directors, including Paritosh Trivedi, Arvind Motilal Agarwal, Ravi Kapoor and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available